/pharmaceuticals/oncology/Gilead-invests-cancer-immunology-focused/98/i29 20200725 Concentrates 98 29 /magazine/98/09829.html Gilead invests in cancer immunology-focused Tizona Oncology, pharmaceuticals, Gilead con bus Lisa M. Jarvis pharmaceuticals oncology Gilead makes investment in Tizona Chemical & Engineering News Gilead invests in cancer immunology-focused Tizona Gilead invests in cancer immunology-focused Tizona
by Lisa M. Jarvis | July 25, 2020
Twist Bioscience is licensing its synthetic antibody phage display libraryto Takeda Pharmaceutical, which will use it to discover antibodies for gasteroenterology, neuroscience, oncology, and rare disease therapies. Twist, a DNA synthesis company, is itself moving into drug development. Entegris has purchased Global Measurement Technologies for $36 million.
July 18, 2020
—Roche buys into Blueprint’s RET inhibitor “The deal positions pralsetinib to compete against Lilly’s Retevmo” Roche is investing $775 million in cash and equity for access to Blueprint Medicines’ oncology drug candidate pralsetinib, which is under review by the US Food and Drug Administration. Pralsetinib is a small-molecule inhibitor of RET alterations—rare genetic fusions or mutations that occur at low levels across lung, thyroid, and many other cancers.
by Lisa M. Jarvis | July 18, 2020
That could make it the first protein degrader to enter human studies outside the field of oncology. /pharmaceuticals/drug-discovery/Sanofi-Kymera-sign-protein-degrader/98/i27 20200711 Concentrates 98 27 /magazine/98/09827.html Sanofi and Kymera sign protein degrader deal Protein degraders, Sanofi, Kymera con bus Lisa M.
by Lisa M. Jarvis | July 11, 2020
/pharmaceuticals/oncology/GSK-Ideaya-seal-synthetic-lethality/98/i24 20200620 Concentrates 98 24 /magazine/98/09824.html GSK and Ideaya seal synthetic lethality pact Oncology, pharmaceuticals, synthetic lethality, biotechnology con bus Lisa M. Jarvis pharmaceuticals oncology GSK and Ideaya seal synthetic lethality pact Chemical & Engineering News GSK and Ideaya seal synthetic lethality pact GSK and Ideaya seal synthetic lethality pact
by Lisa M. Jarvis | June 20, 2020
/pharmaceuticals/oncology/Shattuck-raises-118-million-bifunctional/98/i24 20200620 Concentrates 98 24 /magazine/98/09824.html Shattuck raises $118 million for bifunctional proteins oncology, pharmaceuticals, shattuck labs con bus Ryan Cross pharmaceuticals oncology Shattuck raises funds for bifunctional proteins Chemical & Engineering News Shattuck raises $118 million for bifunctional proteins Shattuck raises $118 million for bifunctional proteins
by Ryan Cross | June 20, 2020
—AbbVie and Genmab sign oncology antibody pact “” AbbVie will pay the Danish antibody specialist Genmab $750 million as part of a deal to commercialize three of Genmab’s biospecific antibodies for cancer. Genmab could get another $3.2 billion in milestone payments. The pact joins Genmab antibodies, which can direct cytotoxic T cells to tumors, with AbbVie’s antibody-drug conjugate technology.
by Michael McCoy | June 13, 2020
/pharmaceuticals/oncology/Bristol-Myers-Squibb-taps-Repares/98/i21 20200529 Concentrates 98 21 /magazine/98/09821.html Bristol-Myers Squibb taps Repare’s CRISPR screens for cancer drug discovery oncology, pharmaceuticals, bms, repare therapeutics, synthetic lethality, crispr screen con bus Ryan Cross pharmaceuticals oncology BMS invests in CRISPR screen firm Chemical & Engineering News Bristol-Myers Squibb taps Repare’s CRISPR screens for cancer drug discovery Bristol-Myers Squibb taps Repare’s CRISPR screens for cancer drug discovery
by Ryan Cross | May 29, 2020
/pharmaceuticals/oncology/Gilead-invests-Arcuss-immunotherapy-pipeline/98/i21 20200529 Concentrates 98 21 /magazine/98/09821.html Gilead invests in Arcus’s immunotherapy pipeline Cancer, immunotherapy, Gilead, Arcus con bus Michael McCoy pharmaceuticals oncology Gilead and Arcus target immunotherapy Chemical & Engineering News Gilead invests in Arcus’s immunotherapy pipeline Gilead invests in Arcus’s immunotherapy pipeline
by Michael McCoy | May 29, 2020